Et åbent, enarmsstudie af profylakse mod Datopotamab Deruxtecan (Dato-DXd)-relateret stomatitis hos kvalificerede patienter med metastatisk eller inoperabel lokal recidiv brystkræft eller lokal fremskreden eller metastatisk epidermal vækstfaktorreceptormuteret ikke-småcellet lungekræft. (TROPION-SWISH)
En fase IV, åben-label, enkeltarmet undersøgelse af profylakse for datopotamab deruxtecan-relateret stomatitis hos kvalificerede patienter med metastatisk eller inoperabel lokal recidiverende brystkræft eller lokal avanceret eller metastatisk epidermal vækstfaktorreceptormuteret ikke-småcellet lungekræft (TROPION-SWISH)
This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal Growth Factor Receptor-Mutated (EGFRm) non-small cell lung cancer
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
The purpose of this Phase IV study is to describe the incidence and severity of Dato-DXd treatment-emergent grade ≥ 2 stomatitis in participants receiving prophylactic dexamethasone mouthwash within the first 12 weeks of study treatment (ie, Dato-DXd dosing).
The study will enroll an estimated 100 participants across approximately 35 sites in the U.S. Enrollment of participants is planned to occur over approximately 18 months, with a minimum of 12 weeks of follow-up for each participant after the first Dato-DXd dose.
This study has one arm, and the study population will consist of 2 independent cohorts (approximately 50 participants in each cohort):
- Breast cohort (Cohort 1)
- Lung cohort (Cohort 2)
Participants will receive the study intervention, dexamethasone mouthwash, throughout the duration of their standard of care treatment with Dato-DXd.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 4
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: AstraZeneca Clinical Study Information Center
- Telefonnummer: 1-877-240-9479
- E-mail: information.center@astrazeneca.com
Studiesteder
-
-
Arizona
-
Tucson, Arizona, Forenede Stater, 85719
- Trukket tilbage
- Research Site
-
-
Arkansas
-
Hot Springs, Arkansas, Forenede Stater, 71913
- Rekruttering
- Research Site
-
Little Rock, Arkansas, Forenede Stater, 72205
- Rekruttering
- Research Site
-
-
California
-
Duarte, California, Forenede Stater, 91010
- Ikke rekrutterer endnu
- Research Site
-
Glendale, California, Forenede Stater, 91204
- Rekruttering
- Research Site
-
Lakewood, California, Forenede Stater, 90805
- Rekruttering
- Research Site
-
Long Beach, California, Forenede Stater, 90806
- Rekruttering
- Research Site
-
Torrance, California, Forenede Stater, 90505
- Ikke rekrutterer endnu
- Research Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20037
- Trukket tilbage
- Research Site
-
-
Florida
-
Coral Springs, Florida, Forenede Stater, 33065
- Rekruttering
- Research Site
-
Plantation, Florida, Forenede Stater, 33322
- Rekruttering
- Research Site
-
-
Georgia
-
Athens, Georgia, Forenede Stater, 30607
- Rekruttering
- Research Site
-
-
Idaho
-
Boise, Idaho, Forenede Stater, 83706
- Trukket tilbage
- Research Site
-
-
Illinois
-
Park Ridge, Illinois, Forenede Stater, 60068
- Trukket tilbage
- Research Site
-
-
Indiana
-
Fort Wayne, Indiana, Forenede Stater, 46825
- Rekruttering
- Research Site
-
-
Kentucky
-
Elizabethtown, Kentucky, Forenede Stater, 42701
- Rekruttering
- Research Site
-
Lexington, Kentucky, Forenede Stater, 40503
- Rekruttering
- Research Site
-
Lexington, Kentucky, Forenede Stater, 40509
- Ikke rekrutterer endnu
- Research Site
-
Louisville, Kentucky, Forenede Stater, 40207
- Rekruttering
- Research Site
-
-
Louisiana
-
New Orleans, Louisiana, Forenede Stater, 70112
- Ikke rekrutterer endnu
- Research Site
-
-
Maryland
-
Frederick, Maryland, Forenede Stater, 21702
- Trukket tilbage
- Research Site
-
Glenn Dale, Maryland, Forenede Stater, 20769
- Ikke rekrutterer endnu
- Research Site
-
-
Michigan
-
Detroit, Michigan, Forenede Stater, 48202
- Ikke rekrutterer endnu
- Research Site
-
Grayling, Michigan, Forenede Stater, 49738
- Rekruttering
- Research Site
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55426
- Rekruttering
- Research Site
-
-
Missouri
-
Kansas City, Missouri, Forenede Stater, 64111
- Rekruttering
- Research Site
-
-
Nevada
-
Reno, Nevada, Forenede Stater, 89502
- Trukket tilbage
- Research Site
-
-
New Hampshire
-
Lebanon, New Hampshire, Forenede Stater, 03756
- Trukket tilbage
- Research Site
-
-
New York
-
East Syracuse, New York, Forenede Stater, 13057
- Rekruttering
- Research Site
-
Westbury, New York, Forenede Stater, 11590
- Ikke rekrutterer endnu
- Research Site
-
White Plains, New York, Forenede Stater, 10601
- Trukket tilbage
- Research Site
-
-
North Carolina
-
Greensboro, North Carolina, Forenede Stater, 27403
- Ikke rekrutterer endnu
- Research Site
-
Wilson, North Carolina, Forenede Stater, 27893
- Rekruttering
- Research Site
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44106
- Ikke rekrutterer endnu
- Research Site
-
-
Pennsylvania
-
Wynnewood, Pennsylvania, Forenede Stater, 19096
- Rekruttering
- Research Site
-
-
South Carolina
-
West Columbia, South Carolina, Forenede Stater, 29169
- Ikke rekrutterer endnu
- Research Site
-
-
Tennessee
-
Knoxville, Tennessee, Forenede Stater, 37920
- Rekruttering
- Research Site
-
-
Virginia
-
Fairfax, Virginia, Forenede Stater, 22031
- Rekruttering
- Research Site
-
-
West Virginia
-
Charleston, West Virginia, Forenede Stater, 25304
- Trukket tilbage
- Research Site
-
Morgantown, West Virginia, Forenede Stater, 26506
- Rekruttering
- Research Site
-
-
Wisconsin
-
Waukesha, Wisconsin, Forenede Stater, 53188
- Rekruttering
- Research Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Patients are eligible to be included in the study only if all the following criteria apply:
Disease Characteristics
-
Patients with any of the following disease characteristics are eligible (specific population subject to FDA Dato-DXd label):
• Patients with unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cancer who have received prior ET and chemotherapy for unresectable or metastatic disease.
OR
• Adult patients with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy. Participants will be enrolled upon FDA approval on use of Dato-DXd for this indication.
OR
• Patients with locally advanced or metastatic EGFRm NSCLC who have received prior EGFR-directed therapy and platinum-based chemotherapy.
Age
-
Patient must be ≥ 18 years, at the time of signing the informed consent.
Type of Patient and Disease Characteristics-
-
Has documentation that Dato-DXd will be prescribed for the labelled indication and has not received any dose of Dato-DXd prior to enrollment.
-
Is willing to comply with use of prophylactic dexamethasone mouthwash at the start of first infusion and throughout Dato-DXd administration.
-
ECOG performance status 0 or 1.
-
Has adequate bone marrow function (hemoglobin ≥ 9 g/dL; red blood cell/plasma transfusion is not allowed within 1 week prior to screening assessment).
-
All women of childbearing potential must have a negative serum pregnancy test result at screening.
Informed Consent
-
Capable of giving signed informed consent as described in the protocol which includes compliance with the requirements and restrictions listed in the ICF and the protocol.
Exclusion Criteria:
Patients are excluded from the study if any of the following criteria apply:
-
Has received Dato-DXd prior to enrollment.
Medical Conditions
-
As judged by the investigator, any evidence of cardiac, pulmonary, vascular, and other renal conditions which in the investigator's opinion makes it undesirable for the patient to participate in the study.
-
Has any-grade active and uncontrolled stomatitis or mouth ulcers at baseline (participants with prior medical history of stomatitis or mouth ulcers are eligible).
-
Use of steroid-containing mouthwash is contraindicated in, including but not limited to:
- Active oral infections (eg, viral, bacterial, or fungal), where the use of a steroid-containing mouthwash may impair local immune response and delay healing
- Known hypersensitivity or allergy to corticosteroids or any excipients contained in the mouthwash formulation
-
Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals; suspected infections (eg, prodromal symptoms); or inability to rule out infections (participants with localized fungal infections of skin or nails are eligible).
-
Has clinically significant corneal disease.
-
Has a history of severe hypersensitivity reactions to either the drug or inactive ingredients of Dato-DXd (including, but not limited to, polysorbate 80).
-
Has a history of severe hypersensitivity reactions to other monoclonal antibodies.
-
Is pregnant, or breastfeeding, or planning to become pregnant.
Other Exclusions
-
Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
-
Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
-
Previous enrollment in the present study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Dexamethasone 0.5 mg/5 mL Mouthwash
Participants will use dexamethasone 0.5 mg/5 mL alcohol-free mouthwash (10 mL, 4 times daily, swish for approximately 2 minutes, then spit out without swallowing). Participants will remain without food or drink for at least 30 minutes after use of dexamethasone |
Dexamethasone steroid-based oral solution, comprised of 0.5 milligrams per 5mL of alcohol-free dexamethasone. Commercially available Dato-DXd is prescribed and administered to participants according to standard of care
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence and severity of Dato-DXd treatment-emergent grade ≥ 2 stomatitis in patients receiving prophylactic dexamethasone mouthwash within first 12 weeks of study treatment
Tidsramme: From date of first dose of study treatment until 12 weeks after date of first dose of study treatment
|
Incidence is defined as the proportion of participants who develop National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 grade ≥ 2 stomatitis accompanied by either a Normalcy of Diet Subscale score ≤ 50 and/or a Numeric Rating Scale (NRS) oral-pain score of 7 on 2 consecutive days or 8, 9, or 10 on any one day. Severity will be based on the highest NCI-CTCAE v5.0 grade of stomatitis experienced by each participant. CTCAE displays Grades 1-5 with descriptions of severity for each adverse event (AE). Grade 1 for mild symptoms and Grade 5 for death related to AE. The Normalcy of Diet Subscale assesses the degree to which a patient can eat a normal diet and drink liquids. The scale is a ranking of 10 food categories, from easy-to-eat to difficult-to-eat. The Numeric Rating Scale is a scale for self-reporting of pain. Scores range from 0-10, with higher scores meaning the worst pain possible (0=no pain to 10=worst possible pain). |
From date of first dose of study treatment until 12 weeks after date of first dose of study treatment
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence and severity of Dato-DXd treatment-emergent grade ≥ 2 stomatitis
Tidsramme: From date of first dose of study treatment until 6 and 9 weeks after date of first dose of study treatment
|
This will be determined using the composite stomatitis definition in the primary outcome. Will be repeated within 6 weeks and within 9 weeks of study treatment. |
From date of first dose of study treatment until 6 and 9 weeks after date of first dose of study treatment
|
|
Incidence and severity of treatment-emergent stomatitis overall, by maximum CTCAE grade, and CTCAE grade ≥ 2
Tidsramme: From date of first dose of study treatment until 6, 9 and 12 weeks after date of first dose of study treatment
|
This will be determined using stomatitis CTCAE grade only. Will be analysed at 6, 9 and 12 weeks. |
From date of first dose of study treatment until 6, 9 and 12 weeks after date of first dose of study treatment
|
|
Time to onset of grade ≥ 2 stomatitis
Tidsramme: From date of first dose until earliest of diagnosis of grade ≥2 stomatitis, Dato-DXD discontinuation and death, whichever occurs first, assessed up to approximately 21 months
|
The time (in days) from the date of the first dose of Dato-DXd to the date of first onset to a grade ≥ 2 stomatitis event. The measure of primary interest is median time to onset. |
From date of first dose until earliest of diagnosis of grade ≥2 stomatitis, Dato-DXD discontinuation and death, whichever occurs first, assessed up to approximately 21 months
|
|
Time to resolution of Dato-DXd-related grade ≥ 2 stomatitis
Tidsramme: From date of diagnosis of grade ≥2 stomatitis until the earliest date of event resolved or reduced in severity to grade 1, assessed up to approximately 21 months
|
Number of days from the date of onset of stomatitis grade ≥ 2 until the earliest date of event resolved or reduced in severity to grade 1. The measure of primary interest is median time to resolution. |
From date of diagnosis of grade ≥2 stomatitis until the earliest date of event resolved or reduced in severity to grade 1, assessed up to approximately 21 months
|
|
Proportion of participants with a dose modification for Dato-DXd due to stomatitis
Tidsramme: From date of first dose until earliest of Dato-DXD discontinuation and death, assessed up to approximately 21 months
|
Dose modification is defined as dose reduction, delay, or discontinuation due to stomatitis Treatment-Emergent Adverse Event (TEAE). |
From date of first dose until earliest of Dato-DXD discontinuation and death, assessed up to approximately 21 months
|
|
Participant adherence to dexamethasone mouthwash
Tidsramme: From date of first dose of study treatment until 12 weeks after date of first dose of study treatment
|
Adherence to dexamethasone mouthwash will be assessed by cohort using the Daily Activities Diary. The measure of primary interest is the median number of swished mouthwashes per day. |
From date of first dose of study treatment until 12 weeks after date of first dose of study treatment
|
|
Safety and tolerability of Dato-DXd in participants receiving prophylactic dexamethasone mouthwash
Tidsramme: From date of first dose of study intervention until 28 days after the last dose (Safety Follow-up), approximately 21 months
|
Safety and tolerability will be evaluated by cohort in terms of AEs (graded by NCI-CTCAE v5.0) and in terms of the following:
|
From date of first dose of study intervention until 28 days after the last dose (Safety Follow-up), approximately 21 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- D926UL00001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD-delingstidsramme
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD-delingsadgangskriterier
When a request has been approved, AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .